Innova Captab Ltd Q2 FY26 — When a ₹380 Crore Quarter Tries to Prove It’s “Innovative” Enough for ₹4,392 Crore Valuation
1. At a Glance
If you ever wanted to see a pharma company that’s equal parts “CDMO workhorse” and “generic medicine street-smart hustler,” welcome to Innova Captab Ltd, trading at ₹768 (as of 7 Nov 2025), down 16% in three months and looking like that student who scored 80% last year but now barely passed chemistry. With a market cap of ₹4,392 crore, the company just dropped Q2 FY26 numbers that made analysts blink twice — Revenue ₹380 crore (↑19.5% YoY), PAT ₹29.7 crore (↓15.2%), and a stoic EBITDA margin at 14.5%.
The stock’s P/E ratio sits at 35.3, which means investors are still paying “innovative” prices for “generic” profits. With ROE at 14.3%, ROCE at 14.6%, and a Debt-to-Equity of 0.33, Innova Captab looks disciplined — the kind of company that pays its EMIs on time but refuses to share a single paisa as dividend (0% payout since forever).
Still, its shiny new Jammu Greenfield plant promises a ₹1,000–₹2,000 crore revenue pipeline. Until then, the company’s quarterly progress looks like your New Year fitness plan — good intention, inconsistent execution.
2. Introduction – The Pharma Player Who Does Everything
Innova Captab is that overachieving cousin who says, “Main sab karta hoon” — and actually does. From CDMO manufacturing to branded generics (domestic and international), to owning Sharon Bio-Medicine, this ₹4,392 crore pharma player has spread itself across the entire pharmaceutical value chain.
Founded in 2005, Innova Captab built its early reputation as a contract manufacturer for India’s biggest pharma names — Cipla, Glenmark, Lupin, Indoco, Ajanta, Eris, and others. Today, it proudly claims 14 out of the top 15 Indian pharma companies as clients and has served over 190+ customers with 2,900+ products. Eight out of ten of these customers have been around for more than five years, meaning loyalty here is real — like your favorite chemist who knows your blood pressure readings by heart.
However, what started as a solid B2B business now has ambitions to become a full-fledged branded player. Innova has launched over 600 products in the domestic market, reaching 1.5 lakh+ pharmacies and doctors, while also exporting to 25 countries across Asia, Africa, and Latin America.
And then came its boldest move — acquiring Sharon Bio-Medicine in June 2023. The acquisition added international formulations and APIs for markets like Canada, UK, Europe, Australia, and Korea, turning Innova from a contract soldier to a mini-army of its own.
But let’s not get too romantic. Despite all the “integration” talk, the company’s Q2 FY26 profit fell 15% QoQ, proving that even “synergies” can take time to find their footing.
3. Business Model – WTF Do They Even Do?
Innova Captab basically has four mini-empires under one pharmaceutical umbrella:
CDMO (Contract Development and Manufacturing Organization): This is the bread and butter. Innova makes medicines for others, offering end-to-end services from product design to regulatory filing to mass manufacturing. Think of it as the “Pharma Zomato” — others order, Innova cooks.
Domestic Branded Generics: With over 600 SKUs in key therapies — cardiovascular, anti-diabetic, dermatology, and CNS — this is their retail avatar. They hustle through 1.5 lakh+ pharmacies, aiming to become the local neighborhood doctor’s favorite alternative to Mankind or Cipla.
International Branded Generics: They export to 25+ countries, mainly developing markets. Because selling paracetamol in Peru or Vietnam often pays better than competing in Andheri.
Sharon Bio-Medicine Business: Acquired during CIRP, Sharon gives Innova a strong international formulation & API backbone, adding serious R&D and manufacturing muscle. Sharon’s products span Cardio, Antifungal, Antidiabetic, and CNS therapies, a neat overlap with Innova’s own segments.
Add to that their 9 manufacturing blocks spread across Baddi, Dehradun, Taloja, and Kathua, plus the new Jammu Greenfield mega facility worth ₹450 crore, and you’ve got a company with capacity to flood markets faster than a WhatsApp forward.
4. Financials Overview
Metric (₹ Cr)
Q2 FY26
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue
380
318
352
+19.5%
+7.9%
EBITDA
56.1
47
52
+19.4%
+7.9%
PAT
29.7
35
31
-15.2%
-4.2%
EPS (₹)
5.18
6.12
5.42
-15.4%
-4.4%
Commentary: Revenue up, profits down — classic manufacturing startup behavior. The company’s EBITDA margin stayed around 14–15%, which is stable but not “blockbuster pharma” territory. EPS slid due to margin compression and higher expenses. The story? Growth is there, but profitability is playing hide and seek.
5. Valuation Discussion – Fair Value Range
Let’s break this down mathematically (and sarcastically):
A. P/E Method: TTM EPS = ₹21.8 Industry average P/E = 32.8 → Fair Value = ₹21.8 × (28–38) = ₹610 to ₹830
C. DCF (conservative growth 12%, WACC 11%): Intrinsic range ≈ ₹680–₹850
Fair Value Range (Educational only): ₹600 – ₹850 (This fair value range is for educational purposes only and is not investment advice.)
6. What’s Cooking – News, Triggers, Drama
Jammu Greenfield Facility: Commissioned with ₹450+ crore investment; expected to add ₹400–500 crore in FY26 revenue and ₹1,000–2,000 crore at peak. The company also got its
